<DOC>
	<DOCNO>NCT01175018</DOCNO>
	<brief_summary>Acute myocardial infarction ( AMI ) remain major cause morbidity mortality . Many patient die early course , survive risk die late adverse cardiac remodel heart failure . The initial ischemic damage myocardium initiate intense inflammatory response promote cardiac dysfunction heart failure . The investigator propose antiinflammatory strategy base blockade Interleukin-1 quench inflammatory response lead favorable cardiac remodel process .</brief_summary>
	<brief_title>Anakinra Prevent Adverse Post-infarction Remodeling ( 2 )</brief_title>
	<detailed_description>Acute myocardial infarction ( AMI ) remain major cause morbidity mortality . Many patient die early course , survive risk die late adverse cardiac remodel heart failure . The initial ischemic damage myocardium initiate intense inflammatory response promote cardiac dysfunction heart failure . Interleukin-1 ( IL-1 ) prototypical inflammatory cytokine involve tissue response injury . In experimental model large anterior wall AMI mouse , IL-1 blockade use anakinra , recombinant human IL-1 receptor antagonist ameliorate cardiac remodel improves survival follow AMI . Although mouse AMI model helpful understanding event lead adverse post-infarction cardiac remodel heart failure , exact role IL-1 patient AMI completely characterize . The investigator propose address question study patient present ST-segment elevation AMI ( STEMI ) . Such patient high risk in-hospital long-term mortality display several marker inflammation . The investigator hypothesize IL-1 blockade patient STEMI limit acute inflammatory response prevent adverse cardiac remodeling , heart failure , related morbidity . The investigator hypothesize treatment anakinra lead favorable cardiac remodeling . Left ventricular end-systolic volume index ( LVESVi ) prefer clinical marker adverse cardiac remodel strong predictor heart failure-related mortality patient STEMI , use primary endpoint study . The investigator propose anakinra reduce change LVESVi baseline 10-14 week STEMI , prevent , least part , change cardiac function exercise tolerance associate adverse cardiac remodel heart failure .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Interleukin 1 Receptor Antagonist Protein</mesh_term>
	<criteria>Patients STEMI ask enroll accord follow inclusion criterion : age &gt; 18 year , acute ( &lt; 12 h ) onset chest pain associate ST segment elevation ( &gt; 2 mm ) 2 anatomically contiguous lead ECG , successful primary percutaneous coronary intervention . Exclusion criterion : inability give inform consent , late presentation ( &gt; 12 h ) , unsuccessful revascularization procedure , hemodynamic instability include hypotension , prior Qwave AMI , endstage congestive heart failure ( American Heart Association [ AHA ] /American College Cardiology [ ACC ] class CD , New York Heart Association IV ) , severe leave ventricular dysfunction ( EF &lt; 20 % ) , severe valvular heart disease , pregnancy , dye allergy contraindication cardiac angiography and/or magnetic resonance imaging , coagulopathy ( INR &gt; 1.5 platelet count &lt; 50000/mm3 ) , recent ( &lt; 14 day ) use antiinflammatory drug ( include NSAIDs ) , chronic inflammatory disease ( include limit rheumatoid arthritis , systemic lupus erythematosus ) , malignancy comorbidity limit survival condition predict inability complete study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>110 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Acute myocardial infarction</keyword>
	<keyword>Heart Failure</keyword>
	<keyword>Cardiac Remodeling</keyword>
</DOC>